{"meta":{"query_hash":"238d4fe56bae","filters":{"venue":"Expert Opinion on Orphan Drugs"},"cohort_total":11,"direct_labels_cover":0,"predictions_cover":11,"exported":11,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/238d4fe56bae","api":"https://metacan.xera.ac/api/v1/cohort?venue=Expert+Opinion+on+Orphan+Drugs"},"results":[{"id":"W1525227301","doi":"10.1517/21678707.2015.1046434","title":"Pathogenic mechanisms and the prospect of gene therapy for choroideremia","year":2015,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Retinal Development and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Spark Therapeutics; National Institutes of Health; Canadian Institutes of Health Research; National Institute for Health and Care Research; Alberta Innovates - Health Solutions; National Eye Institute; Wellcome Trust","keywords":"Choroideremia; Medicine; Genetic enhancement; Bioinformatics; Gene; Genetics; Biology; Ophthalmology","score_opus":0.017600666210098426,"score_gpt":0.27590628969068604,"score_spread":0.2583056234805876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1525227301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035529004,0.92131734,0.0059254975,0.054578975,0.004657623,0.000025513102,0.00007928235,0.000066690525,0.009796196],"genre_scores_gemma":[0.0275307,0.9391885,0.0051263347,0.016974041,0.0054279543,0.000044352353,0.00010327574,0.000027772521,0.005577111],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99967945,0.00010476838,0.000025161227,0.000045215762,0.000111090136,0.0000344305],"domain_scores_gemma":[0.99951136,0.0002691671,0.00007172126,0.00002083632,0.00009234459,0.000034545013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011509878,0.00037485512,0.00057803164,0.00055244286,0.00029277487,0.0011266748,0.00052725675,0.0021287005,0.0032160608],"category_scores_gemma":[0.0011173679,0.00012500903,0.00046385368,0.00028181475,0.0014451853,0.0015912865,0.0005091784,0.00309801,0.0015017964],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006272173,0.00016680386,0.0014835963,0.006020088,0.00012731359,0.0064521325,0.00035466853,0.0013743988,0.065272786,0.17476842,0.12248676,0.6208659],"study_design_scores_gemma":[0.00007199363,0.00030796902,0.0008008414,0.001879246,0.00009321884,0.008866188,0.000190284,0.0005147648,0.010266266,0.044398203,0.9325728,0.00003822025],"about_ca_topic_score_codex":0.00037979204,"about_ca_topic_score_gemma":0.0005610684,"teacher_disagreement_score":0.0032160608,"about_ca_system_score_codex":0.00079921837,"about_ca_system_score_gemma":0.0007221461,"threshold_uncertainty_score":0.010758758},"labels":[],"label_agreement":null},{"id":"W2144559222","doi":"10.1517/21678707.2015.1092868","title":"Potential of antisense therapy for facioscapulohumeral muscular dystrophy","year":2015,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Facioscapulohumeral muscular dystrophy; Gene knockdown; Muscular dystrophy; Homeobox; Medicine; Gene; Genetic enhancement; Transcription factor; Genetics; Bioinformatics; Cancer research; Biology","score_opus":0.019367090787216195,"score_gpt":0.29689671679021246,"score_spread":0.27752962600299624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144559222","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018804627,0.9391281,0.01483483,0.0063887527,0.0026339989,0.00010649378,0.00019631076,0.000115356626,0.017791465],"genre_scores_gemma":[0.12159714,0.84360117,0.008660668,0.004608216,0.0021094976,0.00017924179,0.00037312708,0.00003900018,0.018832019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999882,0.000028738103,0.0000090127205,0.00002422018,0.000039904004,0.000015997282],"domain_scores_gemma":[0.999938,0.000025484105,0.000012417723,0.0000016274379,0.000016487278,0.000006060116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002733443,0.0003589193,0.00042719755,0.00030782112,0.00012535628,0.00043364786,0.00023704533,0.00084580976,0.0037769293],"category_scores_gemma":[0.00018308949,0.00006965144,0.00039068764,0.00013660673,0.00021238373,0.00039046165,0.00023006431,0.0007536985,0.0010875444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053615146,0.0001995972,0.00061335793,0.0065776496,0.00013026678,0.0017211385,0.00018164367,0.00089278416,0.2606012,0.015496999,0.021927578,0.6911217],"study_design_scores_gemma":[0.0002445491,0.002017563,0.0016966641,0.0015224116,0.00027240062,0.005725158,0.00017631304,0.0012770563,0.08839895,0.0064809974,0.89213777,0.000050193506],"about_ca_topic_score_codex":0.0002982651,"about_ca_topic_score_gemma":0.0007486409,"teacher_disagreement_score":0.0037769293,"about_ca_system_score_codex":0.00029656154,"about_ca_system_score_gemma":0.00023051948,"threshold_uncertainty_score":0.012635112},"labels":[],"label_agreement":null},{"id":"W2507172233","doi":"10.1080/21678707.2016.1232649","title":"Applying integrated care systems to rare diseases","year":2016,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.18248556257076873,"score_gpt":0.40905931459993955,"score_spread":0.22657375202917082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507172233","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058469348,0.06925553,0.3258689,0.36220324,0.008985045,0.0016739834,0.0031583654,0.0010784441,0.16930714],"genre_scores_gemma":[0.75386566,0.045815628,0.16489205,0.02002377,0.0056529967,0.0012380589,0.0013002959,0.00010654856,0.0071049994],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.98935246,0.007411341,0.00050417066,0.0005908428,0.0014887112,0.0006523918],"domain_scores_gemma":[0.9882407,0.0063651237,0.001137696,0.0010043685,0.0025478725,0.00070432486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0126626305,0.00058531313,0.0006169245,0.0026076809,0.00081154413,0.0043858876,0.001476573,0.0022051497,0.009313166],"category_scores_gemma":[0.034140453,0.00027182812,0.0012602072,0.003640837,0.0015549621,0.0032502613,0.0055117747,0.0021397327,0.00060825795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016519804,0.00024811135,0.013447529,0.0016401733,0.00092200155,0.00043085671,0.0008873963,0.030611731,0.00027436117,0.5059718,0.04751687,0.39788404],"study_design_scores_gemma":[0.00048809187,0.0005668664,0.015471753,0.0037391249,0.000510809,0.00039364822,0.0016014361,0.05294639,0.00074235856,0.66337436,0.26004794,0.00011716327],"about_ca_topic_score_codex":0.020350123,"about_ca_topic_score_gemma":0.015422779,"teacher_disagreement_score":0.020350123,"about_ca_system_score_codex":0.007927914,"about_ca_system_score_gemma":0.0095781665,"threshold_uncertainty_score":0.06696719},"labels":[],"label_agreement":null},{"id":"W2560073692","doi":"10.1080/21678707.2017.1264300","title":"Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials","year":2016,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Biobank; Clinical trial; Intensive care medicine; Expert opinion; Incidence (geometry); Cancer; Pathology; Internal medicine; Bioinformatics","score_opus":0.15673021908089185,"score_gpt":0.4498017616627763,"score_spread":0.29307154258188445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560073692","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014952974,0.91941154,0.001949406,0.067905374,0.0032764792,0.00014026115,0.0005831315,0.000038910282,0.0051995437],"genre_scores_gemma":[0.046487506,0.887025,0.009053484,0.042822797,0.011728555,0.0006804932,0.001214563,0.00007864032,0.00090899237],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9753675,0.015990054,0.0035930008,0.0014094795,0.0031611682,0.0004789651],"domain_scores_gemma":[0.79314923,0.1725877,0.015479527,0.004480707,0.011148114,0.0031546524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.048769902,0.00036069233,0.0022789747,0.0019745352,0.0005311896,0.0036975772,0.0018504418,0.0021815265,0.008587032],"category_scores_gemma":[0.10647818,0.00032732333,0.0015649318,0.0029488981,0.0023430286,0.0050588963,0.0019109971,0.0034866007,0.0014192578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015037534,0.000094136136,0.0039513577,0.050598264,0.0010336215,0.00037249943,0.00027578106,0.0007369488,0.0005101186,0.024862958,0.069064155,0.84699637],"study_design_scores_gemma":[0.00082113437,0.0008661014,0.005694399,0.11048492,0.0020544177,0.0019665407,0.0006073533,0.0007336178,0.00074169977,0.038908385,0.83704376,0.00007762353],"about_ca_topic_score_codex":0.0012468522,"about_ca_topic_score_gemma":0.0019862093,"teacher_disagreement_score":0.048769902,"about_ca_system_score_codex":0.0025354996,"about_ca_system_score_gemma":0.007982212,"threshold_uncertainty_score":0.257923},"labels":[],"label_agreement":null},{"id":"W2626803060","doi":"10.1080/21678707.2017.1341307","title":"Ultra-orphan drugs: can we afford the price","year":2017,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Orphan drug; Medicine; Pharmacology; Bioinformatics","score_opus":0.24206907623390514,"score_gpt":0.4302075575686553,"score_spread":0.18813848133475017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626803060","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042733067,0.027968775,0.0003610177,0.94945365,0.008960478,0.000010401352,0.00025014623,0.00003541588,0.012532804],"genre_scores_gemma":[0.0396584,0.09290088,0.0019902738,0.7954387,0.04275537,0.00010381531,0.00061680085,0.00024139049,0.026294373],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959495,0.0012477888,0.00021750941,0.00037306963,0.0016510285,0.0005611131],"domain_scores_gemma":[0.98698217,0.0062494637,0.0009537177,0.0005939768,0.0027588787,0.0024618397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063444716,0.0006620993,0.0011277501,0.0009623208,0.0018189992,0.006455992,0.0016425593,0.012073794,0.051937476],"category_scores_gemma":[0.05181113,0.000285083,0.0010367226,0.00088347256,0.0041658427,0.013639106,0.0028582527,0.013713114,0.010907317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015575734,0.000036783473,0.00046994074,0.0003145605,0.000042534484,0.00013438638,0.00014242344,0.000093613766,0.00013492626,0.037686776,0.8824816,0.07830674],"study_design_scores_gemma":[0.0000918223,0.000057437534,0.0008881197,0.0016063162,0.00004637118,0.00020591822,0.0005551717,0.00014546567,0.00012982628,0.052181393,0.94405264,0.000039430975],"about_ca_topic_score_codex":0.014429721,"about_ca_topic_score_gemma":0.024120284,"teacher_disagreement_score":0.051937476,"about_ca_system_score_codex":0.0033127014,"about_ca_system_score_gemma":0.007827349,"threshold_uncertainty_score":0.1737482},"labels":[],"label_agreement":null},{"id":"W2737330112","doi":"10.1080/21678707.2017.1359086","title":"Morbidity and mortality associated with Farber disease and prospects for therapy","year":2017,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital","funders":"National Institutes of Health","keywords":"Medicine; Disease; Intensive care medicine; Adult-onset Still's disease; Internal medicine","score_opus":0.06523544874345108,"score_gpt":0.37822828517479723,"score_spread":0.3129928364313461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737330112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023314217,0.90184766,0.001630056,0.046951253,0.0029090403,0.00003879926,0.0017571301,0.00011276222,0.021439094],"genre_scores_gemma":[0.23923601,0.7340369,0.0019495296,0.0070140613,0.008722549,0.000103949176,0.0032369744,0.00003508357,0.005664834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972445,0.00008082328,0.00002141469,0.000038576414,0.00007081417,0.000063919775],"domain_scores_gemma":[0.9994456,0.00013765396,0.00012928173,0.000015604535,0.000104345665,0.00016744106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072124344,0.00028679473,0.0007951683,0.0004210883,0.00029132227,0.00083917804,0.0004051298,0.0008078553,0.007934645],"category_scores_gemma":[0.0014705796,0.0000641147,0.00069146574,0.0004534424,0.0002724641,0.0004721574,0.00039715596,0.0009777998,0.0013849015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017968458,0.00021542324,0.047671527,0.0043633655,0.00076444424,0.0016511743,0.00014949721,0.0011836342,0.0014407128,0.012297588,0.13282052,0.7956453],"study_design_scores_gemma":[0.0007730589,0.003446897,0.31619197,0.03740708,0.0025158906,0.022397367,0.0018999672,0.0042028497,0.0018431647,0.055387605,0.55367374,0.00026038376],"about_ca_topic_score_codex":0.00082108966,"about_ca_topic_score_gemma":0.00090457813,"teacher_disagreement_score":0.007934645,"about_ca_system_score_codex":0.0007709453,"about_ca_system_score_gemma":0.0009887716,"threshold_uncertainty_score":0.026544094},"labels":[],"label_agreement":null},{"id":"W2895884786","doi":"10.1080/21678707.2018.1536542","title":"Advances in emerging therapeutics for oculopharyngeal muscular dystrophy","year":2018,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oculopharyngeal muscular dystrophy; Muscular dystrophy; Internal medicine","score_opus":0.03677599223228073,"score_gpt":0.34980055287719536,"score_spread":0.31302456064491463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895884786","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031061238,0.97365713,0.0029585804,0.008966401,0.0017944835,0.00004684997,0.0001696474,0.00007503023,0.00922576],"genre_scores_gemma":[0.017306417,0.96713537,0.004307232,0.003896862,0.0016390511,0.00008091374,0.00030640085,0.000021847656,0.0053058327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996748,0.000073723895,0.000030120911,0.000058291935,0.000107036074,0.00005600435],"domain_scores_gemma":[0.9995758,0.00014083,0.000064530184,0.000015484733,0.00015900175,0.000044392968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010375516,0.00059759954,0.00095042156,0.00087583985,0.00027885844,0.0013667679,0.0007118128,0.0014914633,0.008608228],"category_scores_gemma":[0.00066365814,0.00015392214,0.0007507928,0.00049991655,0.00046397172,0.0014875982,0.00074235577,0.0020300932,0.0033106003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046054463,0.00026808077,0.00053827465,0.010131804,0.00015434009,0.00094855804,0.00017394479,0.00078782806,0.027074471,0.016001133,0.047451366,0.8960096],"study_design_scores_gemma":[0.00017170227,0.0007731092,0.0010134474,0.002686844,0.00020257111,0.0016921053,0.00016989265,0.0006072242,0.006621219,0.009462662,0.97656107,0.000038187787],"about_ca_topic_score_codex":0.00055077695,"about_ca_topic_score_gemma":0.001535309,"teacher_disagreement_score":0.008608228,"about_ca_system_score_codex":0.00062861684,"about_ca_system_score_gemma":0.0008892793,"threshold_uncertainty_score":0.028797388},"labels":[],"label_agreement":null},{"id":"W2970900708","doi":"10.1080/21678707.2019.1651641","title":"Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome","year":2019,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Defibrotide; Medicine; Hepatic veno-occlusive disease; Transplantation; Disease; Chemotherapy; Intensive care medicine; Clinical trial; Hematopoietic stem cell transplantation; Surgery; Internal medicine","score_opus":0.018475461179970818,"score_gpt":0.28311162799908024,"score_spread":0.2646361668191094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970900708","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012610819,0.9875694,0.0004498473,0.0040606675,0.0011177587,0.000021554937,0.00009457826,0.000015853255,0.0054091937],"genre_scores_gemma":[0.013408357,0.9751217,0.0014984139,0.004669092,0.0024788175,0.00005278205,0.00026596416,0.000008742503,0.0024961205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972314,0.00007595807,0.00005717508,0.000048055004,0.000070639784,0.000024907507],"domain_scores_gemma":[0.9992951,0.000342482,0.00014494313,0.000015743837,0.00015183842,0.00004981162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075051165,0.0003254954,0.0006924965,0.00090914255,0.000197264,0.00072388526,0.00046977558,0.000822134,0.005994846],"category_scores_gemma":[0.0012394588,0.00010883836,0.0006926721,0.00066760456,0.00027183123,0.0008471241,0.00032771207,0.0016293025,0.0013514066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004469435,0.000098958706,0.0004817101,0.012730804,0.00018824087,0.0006595316,0.00008813792,0.00029101814,0.0027658627,0.00338975,0.037074946,0.94178414],"study_design_scores_gemma":[0.00028460778,0.0006818173,0.0022186425,0.007185784,0.00050734356,0.0036341764,0.00010616229,0.0003484664,0.0015190442,0.0032582171,0.9802186,0.00003711148],"about_ca_topic_score_codex":0.0004024789,"about_ca_topic_score_gemma":0.0011950971,"teacher_disagreement_score":0.005994846,"about_ca_system_score_codex":0.00036475484,"about_ca_system_score_gemma":0.0004835268,"threshold_uncertainty_score":0.020054817},"labels":[],"label_agreement":null},{"id":"W3019361312","doi":"10.1080/21678707.2020.1760837","title":"Advances in therapeutic treatment options for ANCA-associated vasculitis","year":2020,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Rituximab; Maintenance therapy; Intensive care medicine; Guideline; ANCA-Associated Vasculitis; Vasculitis; Cyclophosphamide; Expert opinion; Immunology; Internal medicine; Disease; Chemotherapy; Pathology; Lymphoma","score_opus":0.03436985990012032,"score_gpt":0.3269259203116747,"score_spread":0.2925560604115544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019361312","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060151546,0.96977544,0.0017736622,0.015702091,0.0015810144,0.000024032413,0.000114254144,0.000054409837,0.010373501],"genre_scores_gemma":[0.0076693394,0.975804,0.0030674678,0.0074698594,0.0029753766,0.00004050691,0.00026891104,0.00002114375,0.00268344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999188,0.00023344725,0.000100310135,0.00009231437,0.00031321205,0.000072675335],"domain_scores_gemma":[0.99876225,0.00055747764,0.00019274183,0.000031712436,0.00037493388,0.00008092619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014656096,0.000502005,0.0008465181,0.0011437671,0.00028185532,0.0011856135,0.00072407257,0.0014004263,0.011101584],"category_scores_gemma":[0.0022124934,0.00017048138,0.0010441974,0.0006011391,0.0004382636,0.0015148701,0.00068286073,0.0030311674,0.0035140323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011452367,0.00007758244,0.000427917,0.009027309,0.00013941193,0.0005310435,0.00009387654,0.00043488626,0.0019507831,0.008063782,0.1131719,0.86596704],"study_design_scores_gemma":[0.000057664984,0.00010094147,0.00064600044,0.0064393464,0.00017341823,0.0023328385,0.00006907441,0.00021193591,0.00057063706,0.005002055,0.9843763,0.00001971059],"about_ca_topic_score_codex":0.0011304703,"about_ca_topic_score_gemma":0.0025473828,"teacher_disagreement_score":0.011101584,"about_ca_system_score_codex":0.0007440825,"about_ca_system_score_gemma":0.0010517697,"threshold_uncertainty_score":0.037138462},"labels":[],"label_agreement":null},{"id":"W4385458457","doi":"10.1080/21678707.2023.2241347","title":"Real world data for rare diseases research: The beginner’s guide to registries","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Disease; Medical record; Rare disease; Summary of Product Characteristics; Disease registry; MEDLINE; Product (mathematics); Family medicine; Medical emergency; Data science; Drug; Pathology; Computer science; Pharmacology","score_opus":0.11066388381752931,"score_gpt":0.423275749054378,"score_spread":0.3126118652368487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385458457","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007244351,0.068364285,0.26094785,0.50494546,0.020572415,0.0058942484,0.04769811,0.014155602,0.0766976],"genre_scores_gemma":[0.0070857713,0.100806296,0.68466103,0.10785076,0.018691687,0.012782544,0.036072887,0.005179534,0.026869519],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.89961743,0.05692278,0.01984767,0.0036688827,0.018676732,0.0012664624],"domain_scores_gemma":[0.55041003,0.29277495,0.017484628,0.052956037,0.07450948,0.011864848],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.12348143,0.002110498,0.004049533,0.012998412,0.0019573895,0.014142883,0.008093286,0.011463792,0.048236586],"category_scores_gemma":[0.32892105,0.0035184128,0.0042534783,0.014793292,0.0052790977,0.022348154,0.011506322,0.020340139,0.053391952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008533868,0.000060008286,0.00085680984,0.0021316702,0.000083920255,0.00021997855,0.00059190195,0.00034846997,0.00020057909,0.03335581,0.74365693,0.21840857],"study_design_scores_gemma":[0.000060267063,0.000026481737,0.000521571,0.004596334,0.000027203927,0.00035256997,0.00021866694,0.00026680212,0.00009540897,0.020526882,0.97325474,0.000053171047],"about_ca_topic_score_codex":0.007512,"about_ca_topic_score_gemma":0.008386284,"teacher_disagreement_score":0.87651855,"about_ca_system_score_codex":0.0037350138,"about_ca_system_score_gemma":0.023397598,"threshold_uncertainty_score":0.65304005},"labels":[],"label_agreement":null},{"id":"W4391470543","doi":"10.1080/21678707.2024.2313766","title":"Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Arthur B. McDonald-Canadian Astroparticle Physics Research Institute; Fraser Institute; Wilfrid Laurier University; Canadian Institute for Health Information","funders":"","keywords":"Formulary; Medicine; Orphan drug; Listing (finance); Government (linguistics); Negotiation; List price; Pharmacology; Bioinformatics; Business; Finance; Law; Political science","score_opus":0.12472499760889985,"score_gpt":0.40657598618659424,"score_spread":0.2818509885776944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391470543","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68098,0.11300742,0.0078248335,0.10104281,0.00046898169,0.0009971916,0.027303677,0.00014602495,0.06822911],"genre_scores_gemma":[0.97280526,0.014046808,0.0030994164,0.0032449372,0.00012739153,0.00009069088,0.004982976,0.000020377242,0.0015821592],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98903334,0.002122537,0.0008553461,0.00060554256,0.005708216,0.0016749739],"domain_scores_gemma":[0.9426674,0.020173293,0.020266607,0.0009064215,0.01242442,0.0035619736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013801328,0.00030441937,0.00060654373,0.0041931886,0.001823459,0.0034698118,0.001013151,0.0007803392,0.0039179395],"category_scores_gemma":[0.056118377,0.00022922351,0.0012678318,0.010961391,0.0012274361,0.0012167449,0.0013821877,0.0018157985,0.00014074062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057988445,0.0001582925,0.79717857,0.0018670335,0.0010302417,0.00043077263,0.0008838232,0.008360201,0.00012952594,0.015982484,0.03222426,0.14117493],"study_design_scores_gemma":[0.00013795578,0.00012716053,0.9409635,0.0021135556,0.00066913647,0.0002868776,0.0014658739,0.014997098,0.000370877,0.004426469,0.034337204,0.00010438027],"about_ca_topic_score_codex":0.9670264,"about_ca_topic_score_gemma":0.9691096,"teacher_disagreement_score":0.9278847,"about_ca_system_score_codex":0.07211533,"about_ca_system_score_gemma":0.10392718,"threshold_uncertainty_score":0.5232358},"labels":[],"label_agreement":null}]}